Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAA) is a blank-check company targeting the domestic pharmaceutical manufacturing and life-sciences supply-chain sector. On May 5, 2026, the company filed a Form 425 communication with the SEC — a filing type used exclusively in connection with proposed business combinations — indicating active proceedings toward a merger or acquisition announcement. Form 425 filings are required disclosures made by parties to a business combination and signal that a definitive or prospective transaction is underway. DMAA's sector focus reflects broader investor interest in reshoring drug production to U.S.-based manufacturers. Sign up at SpacDesk for full filing history, deal timeline, and target data on DMAA and hundreds of other SPACs.